Seeking Alpha

coldcoffee123

coldcoffee123
Send Message
View as an RSS Feed
View coldcoffee123's Comments BY TICKER:
Latest  |  Highest rated
  • Amarantus' LymPro Could Be A Game-Changer For Alzheimer's Diagnosis [View article]
    Game Over For AMBS. All can sell their shares on Monday and salvage whatever is left.

    http://bit.ly/14vPpCi
    Sep 8, 2013. 10:46 AM | Likes Like |Link to Comment
  • Voce Capital Turns Up The Heat On Solta, Demands Sale Of Company [View article]
    Hi Scott,

    Solta is looking solid here. Keep up the good work! My apologies, I am at the wrong place, but have you heard of this super-micro bio tech Amarantus BioScience? I see that Jason Napodano is bullish on it and predicting around 30 cents. Is it worth giving a second thought or is this just a pump/dump go-to-hell stuff?
    Sep 6, 2013. 11:47 AM | Likes Like |Link to Comment
  • Amarantus' LymPro Could Be A Game-Changer For Alzheimer's Diagnosis [View article]
    Hi Johnson, I can't tell you that. But I have credible inputs that the LymPro re-runs at BD lab have not reproduced the 98%/96% sensitivity/specificity that AMBS claimed to have achieved in the 160 patient trials.
    Sep 5, 2013. 02:36 AM | Likes Like |Link to Comment
  • Amarantus' LymPro Could Be A Game-Changer For Alzheimer's Diagnosis [View article]
    According to my sources, BD LymPro results have come out of negative. They will not be receiving any funding from BD for CLIA. That is the reason why AMBS had to raise $3M immediately. Expect the stock to trade around $0.035 range later this week.
    Sep 4, 2013. 04:38 PM | Likes Like |Link to Comment
  • Amarin's Stock Price Movement [View instapost]
    Jack, just because someone says 6B, does not mean the company MUST GET THE APPROPRIATE BO offer NOW. Tomorrow if a new analyst comes up and says 60B? Then what? Forget about any BO until 2016. JoeZ is not interested in selling AMRN for dirt. GIA+ANCHOR is in the best interests of the company and the long term shareholders. And that is how it is going to be.
    Sep 3, 2013. 10:40 AM | Likes Like |Link to Comment
  • Yet More New Developmetn Re; Amarin [View instapost]
    No. ANCHOR+GIA is not a fear. It is exactly what the true longs want, contrary to what most analysts continue to sell to their audience. Premature BO will kill any shareholder value. AMRN never needed nor will need BP's charity to be successful. AMRN pps should be worth $80 in 2 years time. Only flippers who want to make a quick 200-400% are misguiding the general public as to what AMRN should do. And don't worry, AMRN has what it takes for a successful launch after ANCHOR approval. Investors should do their independent DD rather than rely on anybody else's personal opinions.
    Sep 1, 2013. 08:18 AM | Likes Like |Link to Comment
  • Amarin's Stock Price Movement [View instapost]
    AMRN is set to GIA after ANCHOR approval. That is the best news that REAL longs wanted to hear. A premature BO would have killed shareholder value. Good job JZ.
    Aug 30, 2013. 11:12 AM | Likes Like |Link to Comment
  • Yet More New Developmetn Re; Amarin [View instapost]
    You got that right. AMRN would be stupid to sell now. Plus, they do not need to. I challenge anyone to give me one good reason why AMRN should sell. They did not sell when they were offered $22 in 2011, then why should they now? I do not see why AMRN should sell itself out because some analysts think they should sell. That to me is hilarious. AMRN is well suited to GIA all the way to REDUCE-IT. I am long AMRN for next 3 years. Investors who know the game, are actually of the opinion that AMRN must not sell. SR has his own opinion, nothing wrong with that. The only problem is it is not the only opinion, and certainly not JZ's.
    Aug 29, 2013. 09:52 AM | Likes Like |Link to Comment
  • Yet More New Developmetn Re; Amarin [View instapost]
    Even if ANCHOR gets approval in Dec, AMRN pps will continue to be in the $5-7 range. It is highly unlikely (almost impossible) that any BP will shell out what JZ is demanding. GIA is the only option left. Buyout will not happen before 2016.
    Aug 28, 2013. 12:49 PM | Likes Like |Link to Comment
  • Amarantus' LymPro Could Be A Game-Changer For Alzheimer's Diagnosis [View article]
    Some of the recent peer-reviewed publications are coming from independent groups working on MANF. How does their success (for whatever indications they are researching on) help AMBS? For example, lets suppose one of these research groups manages to get orphan designation for Fairbanks. How does that help AMBS, other than the fact that it involves MANF? How does MANF patents benefit AMBS for research that is not directly being done by AMBS? Will these groups be required to pay anything to AMBS? Can they refuse to do so? Sorry, I have no idea how patents work !
    Aug 28, 2013. 02:58 AM | Likes Like |Link to Comment
  • Amarantus' LymPro Could Be A Game-Changer For Alzheimer's Diagnosis [View article]
    Any idea why nobody is ready to fund AMBS's research? With Rubinfeld on board, can he not drop a word or two to Amgen? Amgen can spend 11B for Onyx, but nothing for AMBS? They can buy AMBS Diagnostics+Therapeutics for dirt cheap and it could turn out to be great investment. Surely somebody must be eyeing AMBS, don''t you think?? Hard to believe Big Pharma that are always scouting for golden opportunities for acquisition are turning a blind eye to AMBS. Could it be that AMBS is a scam?
    Aug 26, 2013. 05:16 PM | Likes Like |Link to Comment
  • Amarantus Eyes Orphan Indication For MANF [View article]
    BigPapa, What do you mean it is too early to bank on MANF? As an investor, your job should be to find picks that you can buy low and sell high. Who cares if MANF fails down the line. The orphan indications momentum will keep nudging pps higher and that is all you should be worried about. Make 10-20X and move on. There is no small biotech on the horizon with the high-profile advisors, directors, science and upside potential that rivals AMBS's.
    Aug 13, 2013. 09:47 AM | Likes Like |Link to Comment
  • Amarantus Eyes Orphan Indication For MANF [View article]
    Great article. To the point. Jason, the RP annual market being $10B, what back of the envelope pps would you put AMBS at, in case AMBS gets orphan status for RP. Also, I thought the LymPro analytical performance was to complete sometime in Q3, with CLIA study beginning in Q4? Has the timeline been delayed a few months? Also, what is your view on MANF-CED partner? Do you see Germany-based BrainLab a potential candidate? Thanks!!
    Aug 12, 2013. 05:01 PM | 1 Like Like |Link to Comment
  • Yet More New Developmetn Re; Amarin [View instapost]
    I just noticed that AMRN hit yearly low on 26 July 2013, and was approved by FDA on 26 July 2012. This post is off-topic but I would like to know what exactly determines the pps? Is it the company fundamentals or the market or what? And what does it mean by "market"? I mean, what/who decides that ok, the pps needs to be $5.4? Isn't AMRN significantly worth more than that? And why only $5.4? why not $1.3? I mean if ALL know that AMRN should be trading higher, what is it that keeps it at $5 and how is it kept at $5? And then who decides, ok, it is time for AMRN to be at $12 now? Who/what is a MM and its role? If the stocks in general are all undervalued and typically always falling, why do more people not short a stock? Why is shorting not considered illegal? How does shorting helps a company that issues shares to raise money? How is stock trading different from betting in a casino? Why betting in casinos is usually frowned upon in societies worldwide, but stock investing is considered scholarly? A retail investor has no control on the stock price and is at the mercy of the so-called "market" (which i do not know what is it), so in a way stock investing is gambling, isn't it? In a roulette, if you see a series of even numbers, then there is a very high probability of getting odd numbers. So if I bet on an odd number and lose my money, friends and family are ready to beat me up. But if I invest in a very good company and lose money, friends and family say "hard luck, the stock was not supposed to go down." In short, I want to know who/what decides the pps.
    Aug 7, 2013. 10:04 AM | 1 Like Like |Link to Comment
  • Amarantus' LymPro Could Be A Game-Changer For Alzheimer's Diagnosis [View article]
    Jason, you do not mention in your articles other biotechs such as Exonhit, Ctyox, Proteome Biosciences, DiaGenic, that have biomarkers in development ... Does your $0.25 estimate considers competitors?
    Aug 3, 2013. 11:41 AM | Likes Like |Link to Comment
COMMENTS STATS
26 Comments
4 Likes